Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
NCT ID: NCT05399459 Phase: PHASE3 Status: COMPLETED Enrollment: 897 Completion: 2024-01-19
Conditions
Migraine
Interventions
Rimegepant 25 MG, Rimegepant 75 MG, Placebo
Summary
This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of migraine.
Primary Outcome
Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose